InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.00%
)
US TECH 100
19,952.00
(
0.29%
)
Dow Jones
39,344.79
(
0.00%
)
Brent Oil
85.29
(
-0.15%
)
Bitcoin
57,204.35
(
0.88%
)
Post# of 252526
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: poorgradstudent post# 117264

Wednesday, 03/30/2011 9:58:29 AM

Wednesday, March 30, 2011 9:58:29 AM

Post# of 252526

They already have the ASPIRE trial running since last year, so I'm not sure that your point #2 is the most likely concern.



ASPIRE is carfilzomib in combination with Lenalidomide, and Dexamethasone in relapsed MM while FOCUS is the only randomized trial where carfilzomib as single agent in rrMM.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up